A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast ...

I have been on an aromatase inhibitor for the past eight months and have side effects that keep me from having a good quality of life. I am supposed to be on it for five years, but I do not want to ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...

Dr. Steven-Huy Han, a UCLA liver specialist, has prescribed Ocaliva to a handful of patients, although he’s not sure it helps ...

New evidence shows that extended estrogen suppression treatment using aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe; it does not increase the risk of ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a high risk of recurrence. The Food and Drug Administration (FDA) has approved ...

Patients, pathologists, clinicians, researchers, radiologists and others from around the world recently gathered for the 2024 ...

The drug joins abemaciclib (Verzenio ... 3 years of adjuvant treatment with ribociclib plus a non-steroidal aromatase inhibitor reduced the risk of disease recurrence by 25% versus an aromatase ...

Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...

Ability To Add Other Drugs With RLY-2608 Doublet To Go Beyond ... was approved back in 2017 with an aromatase inhibitor [AI] or fulvestrant to treat pre/perimenopausal or postmenopausal women ...